Cancer cachexia contender enters first pivotal trial.
๐๏ธ 2025-10-10
๐ฐ Publication: Nature Reviews Drug Discovery
Read MoreCancer cachexia contender enters first pivotal trial.Cancer-associated_cachexia
Pancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.
<p><b>BACKGROUND</b></p><p>Cancer-associated cachexia (CAC) is a severe metabolic disorder characterized by involuntary weight loss, skeletal muscle atrophy and adipose tissue depletion. It is a major contributor to morbidity and mortality in the advanced stages of various cancers. However, the impact of...
๐๏ธ 2025-10-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePancreatic Damage in Ovarian Cancer-Associated Cachexia Is Driven by Activin A Signalling.Unravelling the Diversity Observed in Cancer Cachexia.
๐๏ธ 2025-10-06
๐ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreUnravelling the Diversity Observed in Cancer Cachexia.New models for cancer cachexia and their application to drug discovery.
Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting...
๐๏ธ 2025-10-03
๐ฐ Publication: Expert Opinion On Drug Discovery
Read MoreNew models for cancer cachexia and their application to drug discovery.Cachexia progression differs among mouse models of metastatic triple-negative breast cancer.
Cancer-associated cachexia decreases quality of life, reduces therapy response, and diminishes survival prospects. Effective cachexia countermeasures remain a significant unmet need. Research into cancer cachexia has made extensive use of models of colon, lung and pancreatic cancers. However, while cachexia...
๐๏ธ 2025-10-03
๐ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreCachexia progression differs among mouse models of metastatic triple-negative breast cancer.Neuroinflammation drives apathy in cancer cachexia.
๐๏ธ 2025-08-13
Read MoreNeuroinflammation drives apathy in cancer cachexia.Vagal blockade of the brain-liver axis deters cancer-associated cachexia.
Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...
๐๏ธ 2025-07-29
๐ฐ Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.Cancer therapy and cachexia.
A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...
๐๏ธ 2025-08-01
๐ฐ Publication: Journal Of Clinical Investigation
Read MoreCancer therapy and cachexia.Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...
๐๏ธ 2025-07-30
๐ฐ Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.Early molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.
๐๏ธ 2025-07-01
๐ฐ Publication: Clinical And Translational Medicine
Read MoreEarly molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.
In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...
๐๏ธ 2025-07-18
๐ฐ Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.
The discovery of immune checkpoints links autoimmunity and cancer, with thymus atrophy reportedly causing autoimmune multiorgan inflammation. The impact of cancer cachexia on thymic involution and its clinical significance remains unclear. This study aimed to investigate this effect and its...
๐๏ธ 2025-08-01
๐ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.
In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...
๐๏ธ 2025-07-15
๐ฐ Publication: British Journal Of Cancer
Read MoreHigh expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.GDF15: from biomarker to target in cancer cachexia.
Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...
๐๏ธ 2025-07-09
๐ฐ Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.
Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...
๐๏ธ 2025-07-03
๐ฐ Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.Pancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.
Pancreatic ductal adenocarcinoma (PDAC) with cachexia-related muscle wasting as the main manifestation is associated with poor overall survival. Extracellular vesicles (EVs) are key mediators of inter-organ communication. Here, EVs and EV-microRNAs (miRNAs) are identified as mediate PDAC-skeletal muscle communication. EVs...
๐๏ธ 2025-07-02
Read MorePancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.